In this panel discussion from our virtual Dublin Innovation Summit  Conference 2021 experts dive deep on FDA’s recent revival of early  feasibility studies in the US. The initial findings from an MDIC working  group indicate that FDA’s efforts to promote early feasibility studies  appear to be working to increase both the number and efficiency of these  trials in the US, demonstrating that, at least on occasion, regulators  can be ahead of industry. Now the burden is on device companies to  follow suit.  

Panelists:

Andrew Glass, CEO, Vivasure Medical

Chip Hance, CEO, Regatta Medical
Jaime Walkowiak, General Counsel, Instil Bio
Aaron V. Kaplan, M.D., Chairman and CMO, Conformal Medical

Moderator: Stephen Levin, Editor-In-Chief, Market Pathways

Read the full article: https://bit.ly/305JF5H

View the latest issue of Market Pathways: https://bit.ly/3uSbUzS

View more podcast episodes: https://bit.ly/3ai8nBy

About Market Pathways

Your premium guide to global medical device regulation, reimbursement  and policy. Market Pathways delivers incomparable intelligence exploring  the people, challenges, and opportunities impacting the global medtech  regulatory and reimbursement community. View the latest issue of Market  Pathways on MyStrategist.com